Study of MAR001 in Adults With Metabolic Dysfunction
- Registration Number
- NCT05896254
- Lead Sponsor
- Marea Therapeutics
- Brief Summary
The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
- Willingness to provide informed consent and comply with the intervention
- Women of childbearing potential and men agreeing to use an appropriate method of contraception for the duration of the study
- Evidence of metabolic dysfunction at screening (triglyceride levels > 2.8 mmol/L)
Exclusion Criteria
- Any condition which in the opinion of the investigator prevents the participant from complying with study procedures or prevents the participant from completing the study or interferes with the interpretation of study results
- Pregnant or breastfeeding mothers
- Terminal illness with expected survival of less than 1 year
Note: additional inclusion/exclusion criteria may apply, per protocol
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description MAR001 MAR001 Subcutaneous injection Placebo Placebo Subcutaneous injection
- Primary Outcome Measures
Name Time Method Safety and tolerability of MAR001 12 weeks Incidence and frequency of treatment-emergent adverse events
- Secondary Outcome Measures
Name Time Method Effect of MAR001 on triglyceride metabolism 12 weeks Change from baseline in triglyceride levels
Trial Locations
- Locations (2)
Melbourne Site
🇦🇺Melbourne, Australia
Brisbane Site
🇦🇺Brisbane, Australia